The early study will only test whether INO-4800 is safe and triggers an immune response.
News & Analysis: Inovio Pharmaceuticals
The company started a clinical trial with its potential new COVID-19 vaccine.
The small biotech has a promising pipeline that includes a potential COVID-19 vaccine. But is that enough to justify buying Inovio stock?
The company may be in line for more COVID-19 grant money.
Investors like the biotech's good news from a phase 2 clinical trial.
An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.
The results from its study of VGX-3100 are an encouraging signal that the biotech's coronavirus vaccine might work too.
Inovio Pharmaceuticals Gets Help From Ology Bioservices and the Defense Department with Its COVID-19 Vaccine Candidate
A $11.9 million Defense Department grant will support the companies as they develop and test INO-4800.
These five biotech stocks could post life-changing gains for early-bird investors.
Both of these companies are in the thick of the hunt to develop a coronavirus vaccine. Which stock is the better pick right now?